Press Releases

OncoSec to Host KOL Event Focused on New ASCO-SITC Melanoma Data and Clinical Strategy on Tuesday, February 28 in New York City

Key Opinion Leaders in Melanoma and Company Representatives to Discuss Unmet Needs in Immunotherapy

SAN DIEGO, Feb. 24, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will host a Key Opinion Leader event to highlight new clinical data that will be featured as an oral and poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and the Company's melanoma development plan. The KOL event will be held in-person and via live webcast on Tuesday, February 28 at 12:00 PM EST / 9:00 AM PST at the Lotte New York Palace Hotel in New York City.

The KOL event will feature a presentation by Alain Algazi, MD, skin cancer specialist in the Melanoma Center at the UCSF Helen Diller Family Comprehensive Cancer Center, who will discuss the latest clinical data from the Phase II Investigator Sponsored Trial led by the University of California, San Francisco. This trial is evaluating the combination of OncoSec's investigational therapy, ImmunoPulse® IL-12, and the approved anti-PD-1 therapy, pembrolizumab in patients with unresectable metastatic melanoma. Additionally, Dr. Algazi will address the current treatment landscape for melanoma patients and describe where there is still an unmet medical need for new treatment options.

Sharron Gargosky, PhD, OncoSec's Chief Clinical and Regulatory Officer, and Chris Twitty, PhD, OncoSec's Director of Clinical Science, will provide an overview of the Company's ongoing clinical research with ImmunoPulse® IL-12 in patients with advanced melanoma who are anti-PD-1 non- responders. Their discussion will focus on the target patient population and the Company's clinical strategy moving forward.

Following the presentation, all presenters will be available for questions. This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend in-person, as space is limited. To reserve a spot, please contact LifeSci Advisors, LLC at mac@lifesciadvisors.com.

To view the live webcast, please access the following link at the time of presentation:  http://lifesci.rampard.com/20170228/reg.jsp. An archived version of the webcast will be available on OncoSec's website: http://ir.oncosec.com/events-presentations.

About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "can," "may," "will," "suggest," "look forward to," "potential," "understand," and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, the following: uncertainties inherent in pre- clinical studies and clinical trials, such as the ability to enroll patients in clinical trials and the risk of adverse events; unexpected new data, safety and technical issues; our ability to raise additional funding necessary to fund continued operations; and the other factors discussed in OncoSec's filings with the Securities and Exchange Commission.

Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

 

CONTACTS:
Punit Dhillon President & CEO
OncoSec Medical Incorporated 855-662-6732
media@oncosec.com

Media:
Laura Radocaj
Dian Griesel International 212-825-3210

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncosec-to-host-kol-event-focused-on-new-asco-sitc-melanoma-data-and-clinical-strategy-on-tuesday-february-28-in-new-york-city-300413032.html

SOURCE OncoSec Medical Incorporated